UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

The New England journal of medicine, 2001-12, Vol.345 (23), p.1667-1675

2001

Volltextzugriff (PDF)

Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure

The New England journal of medicine, 2004-11, Vol.351 (20), p.2049-2057

2004

Volltextzugriff (PDF)

Introduction to surrogate markers

Circulation (New York, N.Y.), 2004-06, Vol.109 (25 Suppl 1), p.IV20-IV21

Cohn, Jay N

2004

Volltextzugriff (PDF)

Effect of the calcium antagonist Felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril : V-HeFT III

Circulation (New York, N.Y.), 1997-08, Vol.96 (3), p.856-863

1997

Volltextzugriff (PDF)

A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure

The New England journal of medicine, 1991-08, Vol.325 (5), p.303-310

1991

Volltextzugriff (PDF)

Arterial stiffness, vascular disease, and risk of cardiovascular events

Circulation (New York, N.Y.), 2006-02, Vol.113 (5), p.601-603

Cohn, Jay N

2006

Volltextzugriff (PDF)

Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling

Journal of the American College of Cardiology, 2000-03, Vol.35 (3), p.569-582

2000

Volltextzugriff (PDF)

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

Journal of hypertension, 2011-04, Vol.29 (4), p.623-635

2011

Volltextzugriff (PDF)

C-reactive protein in heart failure : Prognostic value and the effect of valsartan

Circulation (New York, N.Y.), 2005-09, Vol.112 (10), p.1428-1434

2005

Volltextzugriff (PDF)

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure trial (Val-HeFT)

Circulation (New York, N.Y.), 2003-03, Vol.107 (9), p.1278-1283

2003

Volltextzugriff (PDF)

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)

The American heart journal, 2005-03, Vol.149 (3), p.548-557

2005

Volltextzugriff (PDF)

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

The Lancet (British edition), 2003-03, Vol.361 (9363), p.1077-1083

2003

Volltextzugriff (PDF)

Surrogate markers for cardiovascular disease: functional markers

Circulation (New York, N.Y.), 2004-06, Vol.109 (25 Suppl 1), p.IV31-IV46

2004

Volltextzugriff (PDF)

Lesser Response to Angiotensin-Converting–Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction

The New England journal of medicine, 2001-05, Vol.344 (18), p.1351-1357

2001

Volltextzugriff (PDF)

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT

European heart journal, 2004-02, Vol.25 (4), p.292-299

2004

Volltextzugriff (PDF)

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2004-07, Vol.364 (9431), p.347-354

2004

Volltextzugriff (PDF)

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

The New England journal of medicine, 1986-06, Vol.314 (24), p.1547

1986

Volltextzugriff (PDF)

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

Journal of the American College of Cardiology, 2002-10, Vol.40 (8), p.1414-1421

2002

Volltextzugriff (PDF)

Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure : Results from val-HeFT

Circulation (New York, N.Y.), 2005-08, Vol.112 (8), p.1121-1127

2005

Volltextzugriff (PDF)

Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial (Val-HeFT) echocardiographic data

Journal of the American College of Cardiology, 2004-06, Vol.43 (11), p.2022-2027

2004

Volltextzugriff (PDF)

Cardiovascular Effects of Aldosterone and Post–Acute Myocardial Infarction Pathophysiology

The American journal of cardiology, 2006-05, Vol.97 (10), p.4-12

2006

Volltextzugriff (PDF)

Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)

European journal of heart failure, 2003-10, Vol.5 (5), p.659-667

2003

Volltextzugriff (PDF)

Vascular wall function as a risk marker for cardiovascular disease

Journal of hypertension. Supplement, 1999-12, Vol.17 (5), p.S41-S44

Cohn, J N

1999

Volltextzugriff (PDF)

The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

The New England journal of medicine, 1996-05, Vol.334 (21), p.1349-1355

1996

Volltextzugriff (PDF)

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The valsartan Heart Failure Trial (Val-HeFT)

Circulation (New York, N.Y.), 2002-11, Vol.106 (19), p.2454-2458

2002

Volltextzugriff (PDF)

1 – 25 von 446

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(419)
Mit Volltextzugriff
(377)

Publikationsform

Sprache

Englisch
(446)

Erscheinungsjahr

n.n

Thema

Science & Technology
(432)
Life Sciences & Biomedicine
(429)
Humans
(333)
Cardiovascular System & Cardiology
(296)
Cardiac & Cardiovascular Systems
(255)
Male
(149)
Heart Failure - Drug Therapy
(148)
Biological And Medical Sciences
(138)
Middle Aged
(136)
Medical Sciences
(130)
Heart Failure - Physiopathology
(112)
Peripheral Vascular Disease
(99)
Female
(97)
Aged
(94)
Adult
(91)
General & Internal Medicine
(84)
Medicine, General & Internal
(78)
Animals
(74)
Hemodynamics - Drug Effects
(71)
Cardiovascular System
(67)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure

Introduction to surrogate markers

Effect of the calcium antagonist Felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril : V-HeFT III

A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure

Arterial stiffness, vascular disease, and risk of cardiovascular events

Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

C-reactive protein in heart failure : Prognostic value and the effect of valsartan

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure trial (Val-HeFT)

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

Surrogate markers for cardiovascular disease: functional markers

Lesser Response to Angiotensin-Converting–Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure : Results from val-HeFT

Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial (Val-HeFT) echocardiographic data

Cardiovascular Effects of Aldosterone and Post–Acute Myocardial Infarction Pathophysiology

Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)

Vascular wall function as a risk marker for cardiovascular disease

The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The valsartan Heart Failure Trial (Val-HeFT)

Suchergebnisse filtern